Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 40 entries
Sorted by: Best Match Show Resources per page
[Phonocardiography and differential diagnosis of heart damage in the attack-free course of rheumatism and functional changes in the cardiovascular system in children].

Pediatriia

Liubavin IaG, Kochkin VI.
PMID: 5533284
Pediatriia. 1970 Apr;49(4):44-7.

No abstract available.

Cite
Liubavin IaG, Kochkin VI. Fonokardiografiia v differentsial'noĭ diagnostike porazheniia serdtsa pri bespristupo tekushchem revmatizme i funktsional'nykh izmeniniiakh serdechno-sosudistoĭ sistemy u deteĭ. [Phonocardiography and differential diagnosis of heart damage in the attack-free course of rheumatism and functional changes in the cardiovascular system in children]. Pediatriia. 1970;49(4):44-7
Liubavin, I. a. G., & Kochkin, V. I. (1970). Fonokardiografiia v differentsial'noĭ diagnostike porazheniia serdtsa pri bespristupo tekushchem revmatizme i funktsional'nykh izmeniniiakh serdechno-sosudistoĭ sistemy u deteĭ. [Phonocardiography and differential diagnosis of heart damage in the attack-free course of rheumatism and functional changes in the cardiovascular system in children]. Pediatriia, 49(4), 44-7.
Liubavin, Ia G, and Kochkin, V I. "Fonokardiografiia v differentsial'noĭ diagnostike porazheniia serdtsa pri bespristupo tekushchem revmatizme i funktsional'nykh izmeniniiakh serdechno-sosudistoĭ sistemy u deteĭ." [Phonocardiography and differential diagnosis of heart damage in the attack-free course of rheumatism and functional changes in the cardiovascular system in children]. Pediatriia vol. 49,4 (1970): 44-7.
Liubavin IaG, Kochkin VI. Fonokardiografiia v differentsial'noĭ diagnostike porazheniia serdtsa pri bespristupo tekushchem revmatizme i funktsional'nykh izmeniniiakh serdechno-sosudistoĭ sistemy u deteĭ. [Phonocardiography and differential diagnosis of heart damage in the attack-free course of rheumatism and functional changes in the cardiovascular system in children]. Pediatriia. 1970 Apr;49(4):44-7. Russian. PMID: 5533284.
Copy Download .nbib Format: NLM
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.

Therapeutic advances in urology

Koshkin VS, Small EJ.
PMID: 30574205
Ther Adv Urol. 2018 Nov 11;10(12):445-454. doi: 10.1177/1756287218811450. eCollection 2018 Dec.

Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to inhibit AR-mediated prostate cancer cell proliferation. Following the initial promising clinical efficacy results in phase I and II clinical trials of patients with metastatic castrate-resistant prostate...

Cite
Koshkin VS, Small EJ. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018;10(12):445-454doi: 10.1177/1756287218811450.
Koshkin, V. S., & Small, E. J. (2018). Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Therapeutic advances in urology, 10(12), 445-454. https://doi.org/10.1177/1756287218811450
Koshkin, Vadim S, and Small, Eric J. "Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials." Therapeutic advances in urology vol. 10,12 (2018): 445-454. doi: https://doi.org/10.1177/1756287218811450
Koshkin VS, Small EJ. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Nov 11;10(12):445-454. doi: 10.1177/1756287218811450. eCollection 2018 Dec. PMID: 30574205; PMCID: PMC6295778.
Copy Download .nbib Format: NLM
Binding energies and nonradiative decay rates of Hed micro molecular ions.

Physical review. A, Atomic, molecular, and optical physics

Belyaev VB, Kartavtsev OI, Kochkin VI, Kolganova EA.
PMID: 9912420
Phys Rev A. 1995 Aug;52(2):1765-1768. doi: 10.1103/physreva.52.1765.

No abstract available.

Cite
Belyaev VB, Kartavtsev OI, Kochkin VI, et al. Binding energies and nonradiative decay rates of Hed micro molecular ions. Phys Rev A. 1995;52(2):1765-1768doi: 10.1103/physreva.52.1765.
Belyaev, V. B., Kartavtsev, O. I., Kochkin, V. I., & Kolganova, E. A. (1995). Binding energies and nonradiative decay rates of Hed micro molecular ions. Physical review. A, Atomic, molecular, and optical physics, 52(2), 1765-1768. https://doi.org/10.1103/physreva.52.1765
Belyaev, et al. "Binding energies and nonradiative decay rates of Hed micro molecular ions." Physical review. A, Atomic, molecular, and optical physics vol. 52,2 (1995): 1765-1768. doi: https://doi.org/10.1103/physreva.52.1765
Belyaev VB, Kartavtsev OI, Kochkin VI, Kolganova EA. Binding energies and nonradiative decay rates of Hed micro molecular ions. Phys Rev A. 1995 Aug;52(2):1765-1768. doi: 10.1103/physreva.52.1765. PMID: 9912420.
Copy Download .nbib Format: NLM
[No title available]

Journal for immunotherapy of cancer

de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS.
PMID: 33980590
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002127.

BACKGROUND: Immune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use of tumor genomic profiling in clinical practice may help suggest biomarkers to identify patients most...

Cite
de Kouchkovsky I, Zhang L, Philip EJ, et al. . J Immunother Cancer. 2021;9(5)doi: 10.1136/jitc-2020-002127.
de Kouchkovsky, I., Zhang, L., Philip, E. J., Wright, F., Kim, D. M., Natesan, D., Kwon, D., Ho, H., Ho, S., Chan, E., Porten, S. P., Wong, A. C., Desai, A., Huang, F. W., Chou, J., Oh, D. Y., Pruthi, R. S., Fong, L., Small, E. J., Friedlander, T. W., & Koshkin, V. S. (2021). . Journal for immunotherapy of cancer, 9(5), . https://doi.org/10.1136/jitc-2020-002127
de Kouchkovsky, Ivan, et al. "." Journal for immunotherapy of cancer vol. 9,5 (2021). doi: https://doi.org/10.1136/jitc-2020-002127
de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. . J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002127. PMID: 33980590; PMCID: PMC8118032.
Copy Download .nbib Format: NLM
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.

JAMA oncology

Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL.
PMID: 34137799
JAMA Oncol. 2021 Jun 17; doi: 10.1001/jamaoncol.2021.1799. Epub 2021 Jun 17.

IMPORTANCE: COVID-19 is a life-threatening illness for many patients. Prior studies have established hematologic cancers as a risk factor associated with particularly poor outcomes from COVID-19. To our knowledge, no studies have established a beneficial role for anti-COVID-19 interventions...

Cite
Thompson MA, Henderson JP, Shah PK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021;doi: 10.1001/jamaoncol.2021.1799.
Thompson, M. A., Henderson, J. P., Shah, P. K., Rubinstein, S. M., Joyner, M. J., Choueiri, T. K., Flora, D. B., Griffiths, E. A., Gulati, A. P., Hwang, C., Koshkin, V. S., Papadopoulos, E. B., Robilotti, E. V., Su, C. T., Wulff-Burchfield, E. M., Xie, Z., Yu, P. P., Mishra, S., Senefeld, J. W., Shah, D. P., Warner, J. L. (2021). Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA oncology, . https://doi.org/10.1001/jamaoncol.2021.1799
Thompson, Michael A, et al. "Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19." JAMA oncology vol. (2021). doi: https://doi.org/10.1001/jamaoncol.2021.1799
Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021 Jun 17; doi: 10.1001/jamaoncol.2021.1799. Epub 2021 Jun 17. PMID: 34137799; PMCID: PMC8377563.
Copy Download .nbib Format: NLM
Circulating plasma MicroRNA in patients with active acromegaly.

The Journal of clinical endocrinology and metabolism

Lutsenko A, Belaya Z, Nikitin A, Solodovnikov A, Lapshina A, Koshkin P, Vorontsova M, Rozhinskaya L, Melnichenko G, Dedov I.
PMID: 34550352
J Clin Endocrinol Metab. 2021 Sep 22; doi: 10.1210/clinem/dgab695. Epub 2021 Sep 22.

CONTEXT: Excessive production of growth hormone causes marked multiorgan changes in patients with acromegaly, which may involve epigenetic mechanisms.OBJECTIVE: To evaluate differences in circulating microRNAs (miRNAs) associated with chronic growth hormone overproduction in adults.DESIGN AND SETTING: A cross-sectional case-control...

Cite
Lutsenko A, Belaya Z, Nikitin A, et al. Circulating plasma MicroRNA in patients with active acromegaly. J Clin Endocrinol Metab. 2021;doi: 10.1210/clinem/dgab695.
Lutsenko, A., Belaya, Z., Nikitin, A., Solodovnikov, A., Lapshina, A., Koshkin, P., Vorontsova, M., Rozhinskaya, L., Melnichenko, G., & Dedov, I. (2021). Circulating plasma MicroRNA in patients with active acromegaly. The Journal of clinical endocrinology and metabolism, . https://doi.org/10.1210/clinem/dgab695
Lutsenko, Alexander, et al. "Circulating plasma MicroRNA in patients with active acromegaly." The Journal of clinical endocrinology and metabolism vol. (2021). doi: https://doi.org/10.1210/clinem/dgab695
Lutsenko A, Belaya Z, Nikitin A, Solodovnikov A, Lapshina A, Koshkin P, Vorontsova M, Rozhinskaya L, Melnichenko G, Dedov I. Circulating plasma MicroRNA in patients with active acromegaly. J Clin Endocrinol Metab. 2021 Sep 22; doi: 10.1210/clinem/dgab695. Epub 2021 Sep 22. PMID: 34550352.
Copy Download .nbib Format: NLM
Perioperative management of acquired hemophilia a: a case report and review of literature.

Anesthesiology and pain medicine

Ilkhchoui Y, Koshkin E, Windsor JJ, Petersen TR, Charles M, Pack JD.
PMID: 24660144
Anesth Pain Med. 2013 Dec 27;4(1):e11906. doi: 10.5812/aapm.11906. eCollection 2014 Feb.

INTRODUCTION: Acquired hemophilia A is a rare bleeding disorder with a high mortality rate. Diagnosis and treatment of this disorder can be very challenging to anesthesiologists because of lack of a personal or familial abnormal bleeding history.CASE PRESENTATION: We...

Cite
Ilkhchoui Y, Koshkin E, Windsor JJ, et al. Perioperative management of acquired hemophilia a: a case report and review of literature. Anesth Pain Med. 2013;4(1):e11906doi: 10.5812/aapm.11906.
Ilkhchoui, Y., Koshkin, E., Windsor, J. J., Petersen, T. R., Charles, M., & Pack, J. D. (2014). Perioperative management of acquired hemophilia a: a case report and review of literature. Anesthesiology and pain medicine, 4(1), e11906. https://doi.org/10.5812/aapm.11906
Ilkhchoui, Yashar, et al. "Perioperative management of acquired hemophilia a: a case report and review of literature." Anesthesiology and pain medicine vol. 4,1 (2014): e11906. doi: https://doi.org/10.5812/aapm.11906
Ilkhchoui Y, Koshkin E, Windsor JJ, Petersen TR, Charles M, Pack JD. Perioperative management of acquired hemophilia a: a case report and review of literature. Anesth Pain Med. 2013 Dec 27;4(1):e11906. doi: 10.5812/aapm.11906. eCollection 2014 Feb. PMID: 24660144; PMCID: PMC3961036.
Copy Download .nbib Format: NLM
[Peculiarities of atherosclerotic lesions of lower limb arteries in patients with type 2 diabetes mellitus].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery

Koshkina IV, Nastavsheva OD, Sukhorukov EA, Koshkin VM.
PMID: 25267221
Angiol Sosud Khir. 2014;20(3):24-8.

The authors carried out a comparative study of the arterial vascular wall in patients presenting with atherosclerosis obliterans of lower-limb arteries on the background of diabetes mellitus and without it, thoroughly describing the methodology and reporting the results of...

Cite
Koshkina IV, Nastavsheva OD, Sukhorukov EA, et al. Osobennosti ateroskleroticheskogo porazheniia arteriĭ nizhnikh konechnosteĭ u bol'nykh sakharnym diabetom 2 tipa. [Peculiarities of atherosclerotic lesions of lower limb arteries in patients with type 2 diabetes mellitus]. Angiol Sosud Khir. 2014;20(3):24-8
Koshkina, I. V., Nastavsheva, O. D., Sukhorukov, E. A., & Koshkin, V. M. (2014). Osobennosti ateroskleroticheskogo porazheniia arteriĭ nizhnikh konechnosteĭ u bol'nykh sakharnym diabetom 2 tipa. [Peculiarities of atherosclerotic lesions of lower limb arteries in patients with type 2 diabetes mellitus]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 20(3), 24-8.
Koshkina, I V, et al. "Osobennosti ateroskleroticheskogo porazheniia arteriĭ nizhnikh konechnosteĭ u bol'nykh sakharnym diabetom 2 tipa." [Peculiarities of atherosclerotic lesions of lower limb arteries in patients with type 2 diabetes mellitus]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery vol. 20,3 (2014): 24-8.
Koshkina IV, Nastavsheva OD, Sukhorukov EA, Koshkin VM. Osobennosti ateroskleroticheskogo porazheniia arteriĭ nizhnikh konechnosteĭ u bol'nykh sakharnym diabetom 2 tipa. [Peculiarities of atherosclerotic lesions of lower limb arteries in patients with type 2 diabetes mellitus]. Angiol Sosud Khir. 2014;20(3):24-8. Russian. PMID: 25267221.
Copy Download .nbib Format: NLM
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.

European urology oncology

Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.
PMID: 33423945
Eur Urol Oncol. 2021 Jun;4(3):464-472. doi: 10.1016/j.euo.2020.12.006. Epub 2021 Jan 07.

BACKGROUND: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically useful biomarkers...

Cite
Khaki AR, Li A, Diamantopoulos LN, et al. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021;4(3):464-472doi: 10.1016/j.euo.2020.12.006.
Khaki, A. R., Li, A., Diamantopoulos, L. N., Miller, N. J., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., Koshkin, V., Park, J., Alva, A., Bilen, M. A., Stewart, T., Santos, V., Agarwal, N., Jain, J., Zakharia, Y., Morales-Barrera, R., Devitt, M., Nelson, A., Hoimes, C. J., Shreck, E., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Kumar, V., Lythgoe, M. P., Pinato, D. J., Murgic, J., Fröbe, A., Joshi, M., Isaacsson Velho, P., Hahn, N., Alonso Buznego, L., Duran, I., Moses, M., Barata, P., Galsky, M. D., Sonpavde, G., Yu, E. Y., Shankaran, V., Lyman, G. H., & Grivas, P. (2021). A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European urology oncology, 4(3), 464-472. https://doi.org/10.1016/j.euo.2020.12.006
Khaki, Ali Raza, et al. "A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors." European urology oncology vol. 4,3 (2021): 464-472. doi: https://doi.org/10.1016/j.euo.2020.12.006
Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021 Jun;4(3):464-472. doi: 10.1016/j.euo.2020.12.006. Epub 2021 Jan 07. PMID: 33423945; PMCID: PMC8169524.
Copy Download .nbib Format: NLM
Predictors of tobacco smoking among acutely ill patients in a Moscow hospital: A cross-sectional study.

Tobacco prevention & cessation

Nadezhdin A, Joergenrud B, Tetenova E, Bryun E, Koshkina E, Petukhov A, Kolgashkin A, Kabashi S, Bogstrand ST.
PMID: 32548355
Tob Prev Cessat. 2020 Mar 06;6:18. doi: 10.18332/tpc/117954. eCollection 2020.

INTRODUCTION: Tobacco smoking is a major preventable risk factor for non-communicable diseases. The aim of this study was to investigate predictors of tobacco smoking among acute medically ill patients admitted to a Moscow hospital, and the association between smoking...

Cite
Nadezhdin A, Joergenrud B, Tetenova E, et al. Predictors of tobacco smoking among acutely ill patients in a Moscow hospital: A cross-sectional study. Tob Prev Cessat. 2020;6:18doi: 10.18332/tpc/117954.
Nadezhdin, A., Joergenrud, B., Tetenova, E., Bryun, E., Koshkina, E., Petukhov, A., Kolgashkin, A., Kabashi, S., & Bogstrand, S. T. (2020). Predictors of tobacco smoking among acutely ill patients in a Moscow hospital: A cross-sectional study. Tobacco prevention & cessation, 618. https://doi.org/10.18332/tpc/117954
Nadezhdin, Aleksey, et al. "Predictors of tobacco smoking among acutely ill patients in a Moscow hospital: A cross-sectional study." Tobacco prevention & cessation vol. 6 (2020): 18. doi: https://doi.org/10.18332/tpc/117954
Nadezhdin A, Joergenrud B, Tetenova E, Bryun E, Koshkina E, Petukhov A, Kolgashkin A, Kabashi S, Bogstrand ST. Predictors of tobacco smoking among acutely ill patients in a Moscow hospital: A cross-sectional study. Tob Prev Cessat. 2020 Mar 06;6:18. doi: 10.18332/tpc/117954. eCollection 2020. PMID: 32548355; PMCID: PMC7291909.
Copy Download .nbib Format: NLM
Reply to R. Kebudi et al.

JCO oncology practice

Tsu-Yu Wu J, Kwon DH, Glover M, Henry S, Wood D, Rubin D, Koshkin V, Schapira L, Shah SA.
PMID: 33881937
JCO Oncol Pract. 2021 Jun;17(6):364. doi: 10.1200/OP.21.00105. Epub 2021 Apr 21.

No abstract available.

Cite
Tsu-Yu Wu J, Kwon DH, Glover M, et al. Reply to R. Kebudi et al. JCO Oncol Pract. 2021;17(6):364doi: 10.1200/OP.21.00105.
Tsu-Yu Wu, J., Kwon, D. H., Glover, M., Henry, S., Wood, D., Rubin, D., Koshkin, V., Schapira, L., & Shah, S. A. (2021). Reply to R. Kebudi et al. JCO oncology practice, 17(6), 364. https://doi.org/10.1200/OP.21.00105
Tsu-Yu Wu, Julie, et al. "Reply to R. Kebudi et al." JCO oncology practice vol. 17,6 (2021): 364. doi: https://doi.org/10.1200/OP.21.00105
Tsu-Yu Wu J, Kwon DH, Glover M, Henry S, Wood D, Rubin D, Koshkin V, Schapira L, Shah SA. Reply to R. Kebudi et al. JCO Oncol Pract. 2021 Jun;17(6):364. doi: 10.1200/OP.21.00105. Epub 2021 Apr 21. PMID: 33881937.
Copy Download .nbib Format: NLM
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.

BJU international

Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR.
PMID: 34597472
BJU Int. 2021 Oct 01; doi: 10.1111/bju.15603. Epub 2021 Oct 01.

OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to developing metastatic disease.PATIENTS AND METHODS:...

Cite
Makrakis D, Talukder R, Diamantopoulos LN, et al. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2021;doi: 10.1111/bju.15603.
Makrakis, D., Talukder, R., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., McKay, R. R., Santos, V. S., Agarwal, N., Jain, J., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Grant, M., Lythgoe, M. P., Pinato, D. J., Nelson, A., Hoimes, C. J., Shreck, E., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Murgic, J., Fröbe, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Kumar, V., Di Lorenzo, G., Joshi, M., Isaacsson-Velho, P., Buznego, L. A., Duran, I., Moses, M., Barata, P., Sonpavde, G., Yu, E. Y., Wright, J. L., Grivas, P., & Khaki, A. R. (2021). Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU international, . https://doi.org/10.1111/bju.15603
Makrakis, Dimitrios, et al. "Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer." BJU international vol. (2021). doi: https://doi.org/10.1111/bju.15603
Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2021 Oct 01; doi: 10.1111/bju.15603. Epub 2021 Oct 01. PMID: 34597472.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 40 entries